Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
RYE, N.Y., Nov. 19 /PRNewswire/ -- <!-- cpurl -->Curemark
<!-- /cpurl --> LLC, (www.curemark.com), a drug research and
development company focused on the treatment of neurological
diseases, announced that the company has begun enrolling patients
in Phase III clinical trials for <!-- ppurl -->CM-AT
<!-- /ppurl -->, its autism treatment, at three additional clinical
trial sites. The sites are the Southwest Autism and Resource Center
in Phoenix, Arizona (SARRC); Pennsylvania State University's
Pediatric Clinical Research Office at Hershey Medical Center in
Hershey Pennsylvania; and the University of North Carolina at
Chapel Hill.
Curemark is conducting Phase III clinical trials for CM-AT at 12
sites with a total 170 children across the country. The company
previously announced that the first clinical trial patients were
enrolled at Lake Mary Pediatrics in Orange City, Florida.
"We are extremely pleased with the progress of the Phase III
trial enrollment for CM-AT and are continuing to move forward with
the other sites in the study across the country," said Dr. Joan
Fallon, Curemark founder and CEO. "Especially given the new data on
the increased incidence of autism, we're excited to be this far
along in our clinical program."
CM-AT is based on Fallon's breakthrough research that showed
enzyme deficiencies in autistic children, resulting in an inability
to digest protein. The inability to digest protein affects the
production of amino acids, the building blocks of chemicals
essential for brain function. CM-AT will be one of the first
therapies to address the underlying physiology of autism, rather
than just treat its symptoms.
A new study released in early October by the U.S. Centers for
Disease Control (CDC) showed that the number of children affected
by autism is much higher than originally thought. According to the
CDC, autism affects 1 in 91 children and about 1 in 58 boys,
totaling an estimated 673,000 or approximately 1% of all children
in the U.S.
For information on participating in the CM-AT autism trials, log
on to www.clinicaltrials.gov and search "Curemark."
About CUREMARK LLC
Curemark is a drug research and development company focused on
the treatment of neurological and other diseases, especially those
with dysautonomic components, by addressing certain key
gastrointestinal/pancreatic secretory deficiencies. The company's
initial products are based upon breakthrough observations by its
founder, Dr. Joan Fallon, which revealed a lack of protein
digestion in children with autism and ADHD. To learn more about our
innovative science, visit www.curemark.com
Safe Harbor Statement
This news release contains forward-looking statements that
involve risks and uncertainties that could cause our actual results
and experiences to differ materially from anticipated results and
expectations expressed in such forward-looking statement. These
forward-looking statements include, without limitation, statements
regarding the mechanism of action of CM-AT, its potential
advantages, its potential for use in treating autism, as well as
the timing, progress and anticipated results of the clinical
development and regulatory processes concerning CM-AT. These
statements are based on our current beliefs and expectations as to
such future outcomes, and are subject to known and unknown risks
and uncertainties that may cause actual future experience and
results to differ materially from the statements made. Factors that
might cause such a material difference include, among others, risks
that the results of clinical trials will not support our claims or
beliefs concerning the effectiveness of CM-AT, our ability to
finance our development of CM-AT, regulatory risks, and our
reliance on third party researchers and other collaborators. We
assume no obligation to update these statements, except as required
by law.
Source: Curemark LLC
CONTACT: Michelle Manoff, Rubenstein Public Relations,
+1-212-843-8051,
mmanoff@rubensteinpr.com; or
Dr. Joan Fallon, Curemark LLC, +1-914-925-3450,
joan.fallon@curemark.com
Posted: November 2009
